A Phase I, Dose-escalation Study of a Combination AS703569 and Gemcitabine Given to Subjects With Advanced Malignancies.

Trial Profile

A Phase I, Dose-escalation Study of a Combination AS703569 and Gemcitabine Given to Subjects With Advanced Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2014

At a glance

  • Drugs R 763 (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors EMD Serono; Merck KGaA; Rigel Pharmaceuticals
  • Most Recent Events

    • 23 Aug 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
    • 23 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Apr 2010 Additional lead trial centre and trial investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top